GDTC Stock Summary and Trading Ideas (Cytomed Therapeutics Limited - | NASDAQ:GDTC)

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Cytomed Therapeutics Limited - trades on the NASDAQ stock market under the symbol GDTC.

As of February 17, 2026, GDTC stock price climbed to $1.03 with 27,242 million shares trading.

GDTC has a beta of 0.18, meaning it tends to be less sensitive to market movements. GDTC has a correlation of 0.00 to the broad based SPY ETF.

GDTC has a market cap of $12.09 million. This is considered a Sub-Micro Cap stock.

GDTC has underperformed the market in the last year with a return of -59.8%, while the SPY ETF gained +13.2%. In the last 3 month period, GDTC fell short of the market, returning -48.0%, while SPY returned +2.9%. However, in the most recent 2 weeks GDTC has outperformed the stock market by returning +21.2%, while SPY returned -1.0%.

GDTC support price is $.92 and resistance is $1.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GDTC shares will trade within this expected range on the day.